Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed375%

active_not_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_2

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951

completedphase_2

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699

completedphase_1

Xanamem™ in Healthy Elderly Subjects

NCT03830762

completedphase_2

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

NCT05657691

Clinical Trials (4)

Showing 4 of 4 trials

NCT06125951Phase 2

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Active Not Recruiting

NCT02727699Phase 2

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Completed

NCT03830762Phase 1

Xanamem™ in Healthy Elderly Subjects

Completed

NCT05657691Phase 2

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4